Sundar Jagannath, MBBS

Articles

Dr Jagannath on the Potential Role of MRD Testing for Defining "Cure" in Myeloma

September 5th 2025

Sundar Jagannath, MBBS, explores how minimal residual disease could redefine what it means to achieve a "cure" in multiple myeloma.

Dr Jagannath on the Potential Utility of Linvoseltamab in R/R Multiple Myeloma

August 12th 2024

Sundar Jagannath, MBBS, discusses the potential use of linvoseltamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Dr Jagannath on Linvoseltamab vs Teclistamab in Triple-Class–Exposed R/R Myeloma

June 14th 2024

Sundar Jagannath, MBBS, discusses outcomes with linvoseltamab vs teclistamab in patients with triple-class–exposed, relapsed/refractory multiple myeloma.

Dr Jagannath on Safety Considerations With Ide-Cel in Multiple Myeloma

May 20th 2024

Sundar Jagannath, MBBS, discusses the FDA’s ODAC Meeting on safety considerations with ide-cel in multiple myeloma.

Dr Jagannath on the ODAC Meeting on the Safety of Cilta-Cel in R/R Multiple Myeloma

May 16th 2024

Sundar Jagannath, MBBS, discusses takeaways from the FDA’s ODAC consensus on safety considerations with cilta-cel in relapsed/refractory multiple myeloma.

Dr Jagannath on the Safety of Linvoseltamab in Relapsed/Refractory Multiple Myeloma

May 14th 2024

Sundar Jagannath, MBBS, discusses the safety of linvoseltamab in relapsed/refractory multiple myeloma.

Dr Jagannath on the Safety Considerations With CAR T-Cell Therapy Multiple Myeloma

May 10th 2024

Sundar Jagannath, MBBS, discusses CAR T-cell therapy considerations prior to initiation in the management of multiple myeloma.

Dr Jagannath on the Patient Population in the LINKER-MM1 Trial in Multiple Myeloma

May 3rd 2024

Sundar Jagannath, MBBS, discusses the patient population evaluated in the LINKER-MM1 trial of linvoseltamab in relapsed/refractory multiple myeloma.

Dr Jagannath on the Potential Role for Linvoseltamab in R/R Multiple Myeloma

April 25th 2024

Sundar Jagannath, discusses the potential role for linvoseltamab in relapsed/refractory multiple myeloma.

Dr Jagannath on the Mechanism of Action of Linvoseltamab in R/R Multiple Myeloma

April 19th 2024

Sundar Jagannath, MBBS, discusses the mechanism of action and tolerability of linvoseltamab in patients with relapsed/refractory multiple myeloma.

Dr. Jagannath on the FDA Approval of Cilta-Cel in Relapsed/Refractory Multiple Myeloma

March 3rd 2022

Sundar Jagannath, MBBS, discusses the FDA approval of ciltacabtagene autoleucel in relapsed/refractory multiple myeloma.